Higher urinary excretion of inorganic phosphate during early induction chemotherapy predicts a good prognosis in childhood acute leukemia

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 4, 2011, Pages

  Ichikawa, Mizuho ^a   Kobayashi, Ryoji ^b   Nakajima, Masahide ^c   Inamoto, Jun ^a   Suzuki, Daisuke ^b   Cho, Yuko ^a   Kaneda, Makoto ^d   Yoshida, Makoto ^d   Ariga, Tadashi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAPPORO HOKUYU HOSPITAL   (Japan)

^c Asahikawa City Hospital   (Japan)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

acute lymphoblastic leukemia; acute myeloid leukemia; prognostic factor; tumor lysis syndrome; urine inorganic phosphate

Indexed keywords

ALLOPURINOL; ASPARAGINASE MACROGOL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; METHOTREXATE; MITOXANTRONE; PHOSPHATE; PIRARUBICIN; PREDNISONE; URIC ACID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG RESPONSE; EARLY INTERVENTION; FEMALE; HUMAN; HUMAN CELL; HYPERURICEMIA; INFANT; INFUSION; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URIC ACID URINE LEVEL; URINARY EXCRETION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; PHOSPHATES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URIC ACID;

EID: 79955524701     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181f47040     Document Type: Article

References (22)

1. Vrooman LM, Silverman LB. Childhood acute lymphoblastic leukemia: update on prognostic factors. Curr Opin Pediatr. 2009;21:1-8.
2. Pui C-H. Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Curr Opin Hematol. 1998;5:292.
3. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18-24. (Pubitemid 26019992)
4. Hiddemann W, Clarkson BD, Büchner T, et al. Bone marrow cell count per cubic millimeter bone marrows: a new parameter for quantitating therapy-induced cytoreduction in acute leukemia. Blood. 1982;59:216-225. (Pubitemid 12172006)
5. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia. Cancer. 1997;80:1717-1726. (Pubitemid 27475928)
6. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALLBFM. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310-3322. (Pubitemid 30428458)
7. Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107:2099-2107. (Pubitemid 44665642)
8. Wolfgang K, Torsten H, Claudia S, et al. Early blast clearance by remission induction therapy is major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003;101:64-70.
9. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3-11. (Pubitemid 39331101)
10. Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767-2778.
11. McCroskey RD, Mosher DF, Spencer CD, et al. Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. Cancer. 1990;66:246-250. (Pubitemid 20205903)
12. Horibe K, Hara J, Yagi K, et al. Prognostic factors in childhood acute lymphoblastic leukemia in Japan. Japan Association of Childhood Leukemia Study. Int J Hematol. 2000;72:61-68.
13. Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007-4013.
14. Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J Biol chem. 1925;66:375-400.
15. Domagk GF, Schlicke HH. A colorimetric method using uricase and peroxidase for the determination of uric acid. Anal Biochem. 1968;22:219-224.
16. Heerema NA, Sather HN, Sensel MG, et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (>50 chromosomes). J Clin Oncol. 2000;18:1876-1887. (Pubitemid 30261925)
17. Rubnitz JE, Downing JR, Pui CH, et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol. 2007;15: 1150-1157.
18. Kalwinsky DK, Raimondi SC, Schell MJ, et al. Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol. 1990;8:75-83. (Pubitemid 20032449)
19. Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard risk group in children with AML. Br J Haematol. 1999;104:630-639. (Pubitemid 29119294)
20. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333. (Pubitemid 28452973)
21. Webb DK, Harrison G, Stevens RF, et al. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood. 2001;98:1714-1720.
22. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated, and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107:69-79. (Pubitemid 29500811)